Accessibility Menu
Altamira Therapeutics logo

Altamira Therapeutics(OTC) EARS

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year+37%
1 Month+40%
N/A
Altamira Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.072026-08-27
Altamira Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.29%USD 0.062026-08-20
1 month+39.72%USD 0.052026-07-28
3 month+0%USD 0.072026-05-29
Year to date-24.32%USD 0.092025-12-31
1 year+36.99%USD 0.052025-08-27
3 year-99.05%USD 7.382023-08-28
5 year-99.99%USD 1,100.002021-08-27
Since inception-100%USD 480,000.002014-08-06

Altamira Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

EARS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Altamira Therapeutics

Altamira Therapeutics Ltd. is a biotechnology company focused on developing innovative therapeutic solutions for neurotology and central nervous system disorders. Based in Zug, Switzerland, the company operates with a small team and is advancing several promising candidates through various stages of clinical trials.

Products and Services
  • AM-125: Intranasal betahistine for treating vertigo
  • AM-201: Mitigates antipsychotic-induced weight gain and somnolence
  • AM-111 and Keyzilen (AM-101): Treatments for acute inner ear conditions
Growth Outlook
  • AM-125 and AM-201 are currently in Phase 1 clinical trials
  • AM-111 and Keyzilen are in Phase 3 clinical trials, indicating advanced development
  • Potential for significant market impact in neurotology and CNS disorders
Financial Highlights
  • Market capitalization stands at approximately $4.21 million
  • Cash per share is reported at $2.03, indicating liquidity
  • Price-to-book ratio is notably low at 0.022, suggesting undervaluation
Altamira Therapeutics Ltd. is positioned in a niche market with a focus on unmet medical needs in neurotology and CNS disorders. The company's pipeline includes several candidates that are progressing through clinical trials, which could lead to significant advancements in treatment options. The financial metrics indicate a modest market presence, but the low price-to-book ratio may suggest potential for growth and investment appeal. The ongoing clinical trials and innovative product offerings highlight the company's commitment to addressing critical health challenges.
AI Generated • Aug 13, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Thomas Meyer, PhD

Website

www.altamiratherapeutics.com

Headquarters

Zug, ZUG HM 11, CH

EARS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-111.64%

Return on Capital

N/A

Return on Assets

-84.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Altamira Therapeutics Performance Analysis

Altamira Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Altamira Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -30.508.3%
20232023-12-31USD -8.76-71.3%
20242024-12-31USD -2.99-65.9%
20252025-12-31USD -0.55-81.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HILSHillstream BioPharma, Inc.
$0.24+5.66%
TNFATNF Pharmaceuticals, Inc.
$5.20+48.15%
NBRVFNabriva Therapeutics plc
$0.00+0.00%
VIVSVivoSim Labs, Inc.
$0.29+2.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About EARS

What is the current price of Altamira Therapeutics?

Altamira Therapeutics is trading at N/A per share.

What is the 52-week range for Altamira Therapeutics?

Over the past 52 weeks, Altamira Therapeutics has traded between N/A and N/A.

How much debt does Altamira Therapeutics have?

As of the most recent reporting period, Altamira Therapeutics reported total debt of $1.42M.

How much cash does Altamira Therapeutics have on hand?

Altamira Therapeutics reported $464.00 in cash and cash equivalents in its most recent financial results.

What is Altamira Therapeutics’s dividend yield?

Altamira Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services